Top

Published in:

01-12-2013 | Original Article

Treatment for liver metastasis from renal cell carcinoma with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT): a case series

Authors: Dominik Geisel, Federico Collettini, Timm Denecke, Christian Grieser, Anne Flörcken, Peter Wust, Bernd Hamm, Bernhard Gebauer

Published in: World Journal of Urology | Issue 6/2013

Abstract

Purpose

To retrospectively analyze the clinical outcome of patients with hepatic metastases from renal cell carcinoma who were treated with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT).

Methods

Ten patients (7 men and 3 women; median age 72 ± 7.9 years) with a total number of 16 hepatic metastases from histologically proven renal cell carcinoma were treated with CT-HDRBT after discussing the case in an interdisciplinary tumor conference. All patients had underwent nephrectomy before CT-HDRBT. Three patients had extrahepatic manifestations (2 lung and 1 bone). Six patients had received immunotherapy or targeted therapy before CT-HDRBT. Follow-up included gadoxetic acid (Gd-EOB-DTPA) enhanced MRI two times within 6–8 weeks and after that every 3 months after treatment to evaluate treatment efficacy.

Results

Mean follow-up time was 21.6 ± 13.7 months. One patient developed local and systemic (pulmonary and osseous) progression after 10.8 months which was treated with targeted therapy and died 20.3 months after CT-HDRBT. None of the remaining nine patients developed local progression or died during the follow-up period. Five patients developed systemic progression (3 pulmonary, 1 osseous and 1 locally at the site of nephrectomy) after an average of 19.7 ± 5.5 months.

Conclusions

CT-HDRBT is a viable alternative to hepatic resection of liver metastases from renal cell carcinoma in selected patients.

Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261–2266PubMed

Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966–970PubMedCrossRef

Sengar M, Wadhwa J (2004) Management of metastatic renal cell carcinoma. Indian J Med Paediatr Oncol 25:15

Ruys AT, Tanis PJ, Iris ND et al (2011) Surgical treatment of renal cell cancer liver metastases: a population-based study. Ann Surg Oncol 18:1932–1938PubMedCentralPubMedCrossRef

Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34:193–205PubMedCrossRef

DiBiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG, Corn BW (1997) Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol 158:746–749PubMedCrossRef

Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590PubMedCentralPubMedCrossRef

Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318PubMedCrossRef

Pfannschmidt J, Hoffmann H, Muley T, Krysa S, Trainer C, Dienemann H (2002) Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 74:1653–1657PubMedCrossRef

10.

Aloia TA, Adam R, Azoulay D, Bismuth H, Castaing D (2006) Outcome following hepatic resection of metastatic renal tumors: the Paul Brousse Hospital experience. HPB (Oxford) 8:100–105PubMedCentralCrossRef

11.

Dineen MK, Pastore RD, Emrich LJ, Huben RP (1988) Results of surgical treatment of renal cell carcinoma with solitary metastasis. J Urol 140:277–279PubMed

12.

Rohde D, Albers C, Mahnken A, Tacke J (2003) Regional thermoablation of local or metastatic renal cell carcinoma. Oncol Rep 10:753–757PubMed

13.

Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243:321PubMedCentralPubMedCrossRef

14.

Lencioni R, Cioni D, Crocetti L et al (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation1. Radiology 234:961–967PubMedCrossRef

15.

Shibata T, Iimuro Y, Yamamoto Y et al (2002) Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology 223:331–337PubMedCrossRef

16.

Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK (2000) Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 88:2452–2463PubMedCrossRef

17.

Mohnike K, Wieners G, Schwartz F et al (2010) Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 78:172–179PubMedCrossRef

18.

Schnapauff D, Denecke T, Grieser C et al (2011) Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 35(3):581–587PubMed

19.

Collettini F, Schnapauff D, Poellinger A et al (2012) Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5–7 cm) and very large (>7 cm) tumors. Eur Radiol 22:1101–1109PubMedCrossRef

20.

Ricke J, Mohnike K, Pech M et al (2010) Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 78:479–485PubMedCrossRef

21.

Ricke J, Wust P, Stohlmann A et al (2004) CT-Guided brachytherapy. A novel percutaneous technique for interstitial ablation of liver metastases. Strahlenther Onkol 180:274–280PubMedCrossRef

22.

Ricke J, Wust P, Stohlmann A et al (2004) CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 58:1496–1505PubMedCrossRef

23.

Suppiah R, Shaheen PE, Elson P et al (2006) Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 107:1793–1800PubMedCrossRef

24.

Maldazys JD, deKernion JB (1986) Prognostic factors in metastatic renal carcinoma. J Urol 136:376–379PubMed

25.

Motzer RJ, Bander NH, Nanus DM (1996) Renal-cell carcinoma. N Engl J Med 335:865–875PubMedCrossRef

26.

Adam R, Chiche L, Aloia T et al (2006) Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244:524–535PubMedCentralPubMedCrossRef

27.

Thelen A, Jonas S, Benckert C et al (2007) Liver resection for metastases from renal cell carcinoma. World J Surg 31:802–807PubMedCrossRef

28.

Lewin JS, Nour SG, Connell CF et al (2004) Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience. Radiology 232:835–845PubMedCrossRef

29.

Gebauer B, Werk M, Lopez-Hänninen E, Felix R, Althaus P (2007) Radiofrequency ablation in combination with embolization in metachronous recurrent renal cancer in solitary kidney after contralateral tumor nephrectomy. Cardiovasc Intervent Radiol 30:644–649PubMedCrossRef

30.

Mahnken AH, Günther RW, Tacke J (2004) Radiofrequency ablation of renal tumors. Eur Radiol 14:1449–1455PubMed

Title: Treatment for liver metastasis from renal cell carcinoma with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT): a case series
Authors: Dominik Geisel
Federico Collettini
Timm Denecke
Christian Grieser
Anne Flörcken
Peter Wust
Bernd Hamm
Bernhard Gebauer
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 6/2013
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-012-0981-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment for liver metastasis from renal cell carcinoma with computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT): a case series

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2013

Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry

Efficacy of antibiotic prophylaxis in patients undergoing cystoscopy: a randomized clinical trial

A Population-based survey of lower urinary tract symptoms (LUTS) and symptom-specific bother: results from the Brazilian LUTS epidemiology study (BLUES)

Association of DAZ1/DAZ2 deletion with spermatogenic impairment and male infertility in the South Chinese population

Is stone diameter a variable in the decision process of employing a ureteral stent in patients undergoing uncomplicated ureterorenoscopy and associated intracorporeal lithotripsy?

Shock wave lithotripsy versus ureteroscopy for ureteral calculi: a prospective assessment of patient-reported outcomes